Local

Sanofi, GSK to seek US authorization for COVID-19 vaccine

LONDON (AP) – Doctors Sanofi and GlaxoSmithKline say they will seek approval for regulations for the new COVID-19 vaccine after human trials showed a high level of protection against the disease.

The company said in a statement that the final phase of the trial found that two doses of the vaccine were about 58% effective in preventing infections and 75% effective in preventing moderate or severe disease.

They said that another study on the use of the vaccine as a booster showed that it “caused a significant increase in neutralizing antibodies.”

According to Roger Connor, President of GSK Vaccines, “the evolutionary epidemiology of COVID-19 shows the need for several vaccines.”

“Our protein-based vaccine candidate uses a well-established approach to preventing infection with other viruses, including pandemic flu,” he said. “We are confident that this vaccine can play an important role as we continue to fight this pandemic and prepare for the post-pandemic period.”

Novavax is also seeking authorization for the COVID-19 protein-based vaccine.

At present, Moderna and Pfizer’s two-dose mRNA vaccines are approved by the Food and Drug Administration. Johnson and Johnson’s single-dose vaccine is working with an emergency use permit.



Sanofi, GSK to seek US authorization for COVID-19 vaccine Source link Sanofi, GSK to seek US authorization for COVID-19 vaccine

Related Articles

Back to top button